Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCT1032250187Not yet recruiting
Open-label trial of remimazolam (2 arms). Primary endpoint: Incidence of hypotension. Planned start Jun 2025; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCT1032250187.